Skip to main content

Table 6 Joint effects of AFB1-DNA adducts levels and XPD codon 751 polymorphism on HCC risk

From: XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk

  

Controls

HCCs

  

AFB1-DNA adducts levelsa, b

XPD genotypes

n

%

n

%

OR (95% CI)

Adjusted OR (95% CI)c

Low

LL

257

36.1

64

10.4

Reference

Reference

 

LG

94

13.2

68

11.0

2.90(1.92-4.40)

3.27(2.04-5.26)

 

GG

29

4.1

21

3.4

2.91(1.56-5.43)

3.45(1.71-6.96)

Medium

LL

153

21.5

117

18.9

3.07(2.13-4.42)

3.53(2.33-5.35)

 

LG

44

6.2

40

6.5

3.65(2.20-6.07)

3.56(2.01-6.30)

 

GG

12

1.7

15

2.4

5.02(2.24-11.25)

5.56(2.14-14.44)

High

LL

54

7.6

91

14.7

6.77(4.38-10.44)

8.25(4.97-13.71)

 

LG

49

6.9

114

18.4

9.34(6.06-14.40)

10.42(6.29-17.28)

 

GG

20

2.8

88

14.2

17.67(10.12-30.85)

18.51(9.70-35.30)

  1. a From the likelihood ratio test comparing the fit of the logistic model that included the main effects of AFB1-DNA adducts levels, genotypes and all potential confounders with a fully parameterized model containing the interaction terms of XPD codon 751 genotypes and AFB1-DNA adducts levels (interact term OR = 1.04, P interaction = 0.525).
  2. b AFB1-DNA adducts levels were: ≤ 1.00 μmol/mol DNA for low; 1.01 -- 2.00 f μmol/mol DNA for medium; ≥ 2.01 μmol/mol DNA for high.
  3. c Adjusted for age, sex, ethnicity, HBsAg, anti-HCV, and AFB1-exposure years.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us